MetaCap

Cypherpunk Technologies (CYPH) vs Keros Therapeutics (KROS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Keros Therapeutics (KROS) has outperformed Cypherpunk Technologies (CYPH) over the past year, losing 36.3% versus a loss of 38.2%. Over five years, KROS leads with a -80.2% price change compared with -94.4% for CYPH. Keros Therapeutics is the larger company by market cap ($217.4 million vs $210.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYPH-38.16%KROS-36.29%
+89%+2%-85%
Nov 21, 20251 yearNov 20, 2026
CYPH-93.79%KROS-81.48%
+50%-28%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYPH versus KROS key metrics
MetricCYPHKROS
Share price$1.41$11.08
Market cap$210.15M$217.44M
1-day change-18.02%-2.72%
YTD return+21.55%-45.58%
1-year return-38.16%-36.29%
5-year return-94.45%-80.25%
P/E ratio (TTM)0.67—
EPS (TTM)$2.09$-2.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$243.86M
Net income (latest FY)$4.82M$87.01M
Operating margin—27.71%
Net margin—35.68%
52-week high$4.19$22.55
52-week low$0.491$8.98
Distance from 52-week high-66.35%-50.86%
Analyst consensusstrong_buybuy
Avg. price target upside+254.61%+78.97%
Average volume15.42M196.50K
Shares outstanding149.04M19.62M
Employees687
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cypherpunk Technologies

CYPH stock →

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Keros Therapeutics

KROS stock →

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

CYPH vs KROS FAQ

Which is bigger, Cypherpunk Technologies or Keros Therapeutics?

Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $210.15M for Cypherpunk Technologies (CYPH).

Which stock has performed better over the past year, CYPH or KROS?

KROS returned -36.29% over the past 12 months, compared with -38.16% for CYPH (price return, excluding dividends). Past performance does not predict future results.

Are Cypherpunk Technologies and Keros Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons